KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBITDA Margin (2017 - 2025)

Biomarin Pharmaceutical's EBITDA Margin history spans 16 years, with the latest figure at 5.1% for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 2670.0% year-over-year to 5.1%, compared with a TTM value of 7.92% through Dec 2025, down 948.0%, and an annual FY2025 reading of 12.71%, down 425.0% over the prior year.
  • EBITDA Margin for Q4 2025 was 5.1% at Biomarin Pharmaceutical, down from 2.59% in the prior quarter.
  • The five-year high for EBITDA Margin was 21.6% in Q4 2024, with the low at 14.65% in Q4 2021.
  • Average EBITDA Margin over 5 years is 7.49%, with a median of 8.01% recorded in 2023.
  • Year-over-year, EBITDA Margin crashed -16667bps in 2021 and then soared 1738bps in 2024.
  • Tracing BMRN's EBITDA Margin over 5 years: stood at 14.65% in 2021, then surged by 83bps to 2.43% in 2022, then skyrocketed by 273bps to 4.22% in 2023, then soared by 412bps to 21.6% in 2024, then tumbled by -124bps to 5.1% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's EBITDA Margin are 5.1% (Q4 2025), 2.59% (Q3 2025), and 21.42% (Q2 2025).